Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559323 · ClinicalTrials.gov registry record
LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 2,000
- Enrollment target
NCT02559323: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02559323 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 2,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02559323 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
Cancer survivors face unique health challenges as a result of their cancer diagnosis and treatment. OncoLink created an Internet based program for survivors to learn about their risks. A follow up survey will allow us to continue to develop the program in ways that will benefit users. This survey will need to be conducted via email, which will require the collection of the users email address and a secure method of linking the users care plan questionnaire answers to their survey answers.
Interventions
- OTHER Survey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2010-05 |
| Est. Completion | 2016-07 |
What the finished NCT02559323 record still lists
NCT02559323 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Survey is the first listed.
NCT02559323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02559323 about?
NCT02559323 is a clinical study titled "LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey". Cancer survivors face unique health challenges as a result of their cancer diagnosis and treatment. OncoLink created an Internet based program for survivors to learn about their risks. A follow up survey will allow us to continue to develop the program in ways that will benefit users. This survey wi...
What is the current status of trial NCT02559323?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2010-05. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02559323?
The interventions under investigation include: Survey (OTHER).
Who is sponsoring clinical trial NCT02559323?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia